RALEIGH, N.C.--(BUSINESS WIRE)--BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced a license and supply agreement with TTY Biopharm Co., Ltd., for the exclusive rights to develop and commercialize BEMA Fentanyl (marketed as ONSOLIS in the U.S.) in the Republic of China, Taiwan. The agreement results in potential milestone payments to BDSI of up to $1,300,000, which includes an upfront payment of $300,000. In addition, BDSI will receive an ongoing royalty based on net sales.
